首页|Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma

Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
AIM:To correlate cyclooxygenase-2 (COX-2) expression profile with clinical and pathological variables to assess their prognostic/predictive value in colorectal carcinoma (CRC).METHODS:Archival tumor samples were analyzed using immunohistochemistry for COX-2 expression in 94patients with CRC.Patients were diagnosed and treated at the Departments of Surgery and Oncology,King Abdulaziz University Hospital,Saudi Arabia.RESULTS:Fifty-six percent of the tumors showed positive cytoplasmic COX-2 expression,whereas 44％ of cases were completely COX-2-negative.There were no significant correlations between COX-2 expression and sex,age,grade or tumor location.However,COX-2 expression revealed a significant correlation with tumor stage (P =0.01) and distant metastasis (P =0.02),and a borderline association with lymph node involvement (P=0.07).Tumors with high COX-2 expression showed a higher recurrence rate than tumors with no expression (P ＜ 0.009).In univariate Kaplan-Meier survival analysis,there was a significant (P =0.026) difference in disease-free survival between COX-2-positive and negative tumors in favor of the latter.COX-2 expression did not significantly predict disease-specific survival,which was much shorter for COX-2-positive tumors.In multivariate (COX) models,COX-2 did not appear among the independent predictors of disease-free survival or disease-specific survival.CONCLUSION:COX-2 expression seems to provide useful prognostic information in CRC,while predicting the patients at high risk for recurrent disease.

Colorectal carcinomaCyclooxygenase-2ImmunohistochemistryDisease outcomeAdjuvant therapy

Jaudah AI-Maghrabi、Abdelbaset Buhrneida、Eman Emam、Kari Syrj(a)nen、Abdulrahman Sibiany、Mohmmad AI-Qahtani、Mahmoud AI-Ahwal

展开 >

Department of Pathology,King Abdulaziz University, Jeddah 21589, Saudi Arabia

Center of Excellence in Genomic Medicine Research,King Abdulaziz University, Jeddah 21589, Saudi Arabia

Department of Oncology and Radiotherapy,Turku University Hospital, T-Hospital(Administration), FIN-20521 Turku, Finland

Department of Surgery,king Abdulaziz University, Jeddah 21589,Saudi Arabia

Department of Medicine, Scientific Chair for Colorectal Cancer, King Abdulaziz University, Jeddah 21589,Saudi Arabia

展开 >

2012

10.3748/wjg.v18.i15.1793

世界胃肠病学杂志(英文版)
太原消化病研治中心

世界胃肠病学杂志(英文版)

SCI
影响因子：1.001
ISSN：1007-9327
年,卷(期)：2012.18(15)
  • 3
  • 31